Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8TBF4
UPID:
ZCRB1_HUMAN
Alternative names:
U11/U12 small nuclear ribonucleoprotein 31 kDa protein
Alternative UPACC:
Q8TBF4; Q6PJX0; Q96TA6
Background:
Zinc finger CCHC-type and RNA-binding motif-containing protein 1, also known as U11/U12 small nuclear ribonucleoprotein 31 kDa protein, plays a crucial role in the post-transcriptional modification of RNA. Its unique structure, characterized by the zinc finger CCHC-type and RNA-binding motifs, enables it to interact with RNA in a highly specific manner, facilitating various RNA metabolic processes.
Therapeutic significance:
Understanding the role of Zinc finger CCHC-type and RNA-binding motif-containing protein 1 could open doors to potential therapeutic strategies. Its involvement in RNA metabolic processes makes it an intriguing target for drug discovery, aiming to modulate RNA-related diseases.